The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Pharmaceutical Technology on MSN12d
NHS proposes phased launch for Eli Lilly’s MounjaroThe roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...
Weight-loss and diabetes drugs like Ozempic and Mounjaro could be used to treat drug and alcohol addiction in the future — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback